Aclaris Therapeutics Inc. (NASDAQ:ACRS)’s share price shot up 1.8% during mid-day trading on Thursday . The company traded as high as $21.22 and last traded at $20.52, with a volume of 55,831 shares changing hands. The stock had previously closed at $20.16.

A number of brokerages have recently issued reports on ACRS. Zacks Investment Research upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, August 29th. Jefferies Group increased their price objective on shares of Aclaris Therapeutics from $20.00 to $23.00 and gave the company a “buy” rating in a research note on Friday, August 12th. Finally, Guggenheim started coverage on shares of Aclaris Therapeutics in a research report on Friday, June 10th. They set a “buy” rating and a $35.00 target price for the company. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Aclaris Therapeutics presently has an average rating of “Buy” and a consensus target price of $29.25.

The stock’s market capitalization is $446.72 million. The stock has a 50 day moving average price of $20.09 and a 200 day moving average price of $19.19.

Aclaris Therapeutics (NASDAQ:ACRS) last released its earnings results on Thursday, August 11th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.61) by $0.01. On average, equities analysts expect that Aclaris Therapeutics Inc. will post ($2.61) earnings per share for the current fiscal year.

In other Aclaris Therapeutics news, insider Kamil Ali-Jackson sold 3,738 shares of Aclaris Therapeutics stock in a transaction on Friday, August 26th. The shares were sold at an average price of $20.35, for a total transaction of $76,068.30. Following the completion of the transaction, the insider now directly owns 20,289 shares of the company’s stock, valued at $412,881.15. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies in dermatology. The Company’s drug candidate, A-101 is being developed as an in-office treatment for seborrheic keratosis, a non-cancerous skin tumor, as well as for other cutaneous indications, such as common warts.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.